Boston Scientific Acquires Bolt Medical to Advance Intravascular Lithotripsy Innovation in Cardiovascular Care

Introduction to the Current Status of Cardiovascular Diseases

Globally, cardiovascular diseases loom like the Sword of Damocles, posing a severe threat to human health. According to authoritative data, cardiovascular diseases are one of the leading causes of death and disability worldwide, with a large population succumbing to them annually. Many survivors also experience a significant decline in quality of life, facing long-term suffering from their conditions.

From the perspective of incidence data, with the acceleration of population aging and changes in people's lifestyles, the incidence of cardiovascular diseases is showing an increasing trend year by year. Among various cardiovascular diseases, coronary artery disease is particularly common, with its main causes being cholesterol deposition and calcium buildup inside blood vessels. This leads to vascular stenosis, obstructing normal blood flow, and subsequently triggering a series of severe health issues such as myocardial infarction and heart failure. These diseases not only cause immense suffering to patients but also impose a heavy economic burden on families and society.

In response to the severe situation of cardiovascular disease prevention and treatment, the medical field urgently needs innovative technologies and treatment solutions to overcome the limitations of existing treatment methods and better meet patients' treatment needs.Against this backdrop, Boston Scientific Corporation's completion of the acquisition of Bolt Medical, Inc. is of great significance, and it is highly likely to bring new hope for the treatment of cardiovascular diseases.

Details of the Acquisition

This year, Boston Scientific Corporation successfully completed the acquisition of Bolt Medical, Inc., a development that has drawn widespread attention in the medical field.As early as January 2025, Boston Scientific Corporation first announced its intention to acquire Bolt Medical, Inc. for up to $664 million.Boston Scientific Corporation, as a company with significant influence in the medical device industry, has been closely monitoring the development of Intravascular Lithotripsy (IVL) technology. The innovative achievements of Bolt Medical in the IVL technology field have caught the attention of Boston Scientific.

It is worth mentioning that Boston Scientific Corporation is not entering the Bolt Medical, Inc. arena for the first time. Prior to this, it was already a strategic investor in Bolt Medical, holding approximately 26% of the equity. This acquisition can be seen as Boston Scientific's further expansion into the IVL technology field and an important step in perfecting its cardiovascular product portfolio.

The successful completion of this acquisition was crucially facilitated by the FDA's approval of Bolt Medical's IVL system.Following FDA approval of Bolt Medical's IVL system for marketing and sales across the United States, Boston Scientific swiftly advanced the acquisition process and completed the purchase of Bolt Medical.This approval not only opens the market door for Bolt Medical's IVL technology but also allows Boston Scientific to see its significant commercial potential and clinical application prospects.

Although Boston Scientific Corporation did not announce this news in its official press release, it shared the latest developments on the acquisition via social media. On its LinkedIn page, Boston Scientific expressed anticipation for the acquisition: "We look forward to advancing the IVL therapy developed by Bolt, which will complement our cardiovascular portfolio by expanding treatment options for coronary and peripheral artery diseases." This statement clearly reflects Boston Scientific's high regard for Bolt Medical’s IVL technology and its confidence in achieving greater breakthroughs in the field of cardiovascular disease treatment.

Exploring IVL Technology

(1) Technical Principle

IVL Technology, or Intravascular Lithotripsy, is a novel interventional treatment method specifically targeting severe calcified plaque lesions. Its mechanism resembles an intricate microscopic surgery. In cardiovascular diseases, vascular calcification poses a challenging issue as it reduces arterial compliance and significantly affects both short-term and long-term clinical outcomes after revascularization. Coronary and peripheral artery calcifications are not uncommon in patients undergoing percutaneous interventions. Such calcifications can restrict vessel dilation, lead to higher residual stenosis, reduce the effectiveness of interventional treatments, and may also weaken the antiproliferative effects of drug-coated balloons. Worse still, in patients with arterial calcification, the incidence of complications associated with percutaneous transluminal angioplasty or stent implantation—such as dissections, perforations, and distal embolisms—increases while the long-term patency rate decreases.

The emergence of IVL technology has brought hope for solving these difficult problems. It utilizes a balloon-based conduction system to precisely transmit acoustic shock waves to calcified plaques. Specifically, when the balloon reaches the lesion site, it is expanded at low pressure so that the balloon tightly adheres to the vessel wall. At this point, the system releases unfocused, circumferential, and pulsed mechanical energy to the lesion, generating brief bursts of acoustic pressure waves. These acoustic pressure waves act like tiny "blasters," effectively breaking up calcified lesions with pressure shocks, causing the calcified plaque to form multiple small internal fractures. This fragmentation not only enlarges the lumen area and improves vascular compliance but also ensures the integrity of the vascular intima, creating favorable conditions for subsequent balloon pre-dilation and stent implantation. Compared with traditional treatment methods, IVL technology can break up calcified plaques more accurately, reduce damage to surrounding normal tissues, and has a lower risk of complications, bringing revolutionary changes to the treatment of cardiovascular diseases.

(II) Characteristics of Bolt Medical's IVL System

Bolt Medical's IVL system stands out in this field, utilizing a unique laser-based technology. The system's operation is a precise journey of energy conversion.

First, the laser energy is transmitted to the tip of the balloon catheter through an optical fiber. The optical fiber acts as an efficient energy channel, capable of precisely directing the high-energy laser generated by the laser device to the target position. When the laser energy reaches the interior of the low-pressure inflated balloon, part of the energy interacts with the gas inside the balloon. Under specific conditions, the laser energy is sufficient to ionize the gas molecules, forming a plasma.

The formation of plasma is a crucial step, acting like an "amplifier" of energy that releases a large amount of energy instantly, causing the surrounding gas to expand rapidly. This rapid expansion generates a strong shock wave, whichSound Pressure Wave 。

When the sound pressure wave acts on calcified tissue, the energy it carries is sufficient to cause structural damage within the calcified tissue. The initial pressure wave can create tiny cracks and fractures inside the calcified tissue. As the sound pressure wave propagates through the calcified tissue, it also induces cavitation. Cavitation refers to the process of bubble formation in a liquid. When the negative pressure phase of the sound pressure wave acts on the liquid, the internal pressure of the liquid decreases, leading to the formation and growth of bubbles. Subsequently, during the positive pressure phase of the sound pressure wave, the bubbles rapidly contract and collapse, generating secondary pressure shocks. The bursting pressure of these cavitation bubbles further expands the cracks within the calcified tissue, making the destruction of the calcified tissue more thorough.

In addition to its unique energy conversion mechanism,The Bolt IVL System is also equipped with a visible directional emitter.. This design enables the system to emit energy in a specific direction rather than dispersing it uniformly in all directions. In this way, the system can selectively and precisely transmit energy to areas such as concentric, eccentric, and nodular calcified lesions. Different types of calcified lesions have varying treatment requirements and levels of difficulty; this precise energy transmission capability allows for better handling of various complex calcified conditions, significantly improving the accuracy and safety of treatments. Additionally, the emitter is equipped with an on/off function, allowing doctors to flexibly control energy emission based on actual treatment needs.

In practical applications, the Bolt IVL System has demonstrated numerous advantages. During treatment, the number of available therapeutic pulses has increased, meaning the catheter can emit shock waves more times. This not only provides patients with a more effective treatment option but also reduces the frequency of catheter replacement, lowering surgical costs. In terms of delivery performance, the Bolt IVL System features a smaller diameter and streamlined design, allowing it to pass through narrow or tortuous blood vessels more easily, reducing damage and resistance to the vascular wall, and improving the catheter’s trackability. During advancement, it can withstand significant counterforce without bending or deforming, maintaining stable pushability even when facing complex vascular structures or calcified plaques.

Strategic Considerations Behind the Acquisition

(1) Boston Scientific's Layout

Boston Scientific Corporation's Acquisition of Bolt Medical: A Strategic Move in the Cardiovascular FieldFrom the perspective of product portfolio, Bolt Medical's IVL technology serves as a crucial piece of the puzzle, perfectly complementing Boston Scientific's existing cardiovascular product system. In the treatment of coronary artery disease, although Boston Scientific previously had various treatment methods, there were still certain limitations in handling complex calcified lesions. The Bolt IVL System can precisely break down calcified plaques, offering new treatment options for patients with coronary artery disease. When combined with Boston Scientific’s original coronary intervention products, it enables the creation of more comprehensive and efficient treatment solutions.

In addressing peripheral diseases, Boston Scientific can also optimize treatment strategies by leveraging Bolt Medical's IVL technology. Peripheral artery disease is often accompanied by vascular stenosis and calcification, where traditional treatment methods are less effective in dealing with these complex lesions. The unique advantage of the Bolt IVL system lies in its ability to effectively manage calcified lesions and improve vascular patency, significantly enhancing Boston Scientific's competitiveness in the field of peripheral artery disease treatment.

This acquisition holds profound significance for Boston Scientific's future innovation and development. Bolt Medical's R&D achievements in the IVL technology field provide Boston Scientific with an entirely new technological platform. Boston Scientific can use this as a foundation to further conduct in-depth research and innovation, explore the integration of IVL technology with other cutting-edge technologies, and develop more innovative products that meet the needs of different patients. By integrating the R&D resources and technical strengths of both parties, Boston Scientific is expected to achieve more breakthroughs in the field of cardiovascular disease treatment and lead the industry's development trend.

(II) Industry Competition Situation

Johnson & Johnson's $13 Billion Acquisition of Shockwave Medical in 2024 Creates a Stir in the Intravascular Lithotripsy Field

Under such a competitive landscape, Boston Scientific's acquisition of Bolt Medical appears particularly urgent. Boston Scientific is well aware that to compete with Johnson & Johnson in the IVL field, it must possess unique technological and product advantages. The IVL technology of Bolt Medical differs from that of Shockwave Medical in principle and application. By acquiring Bolt Medical, Boston Scientific can create a differentiated competitive edge. The Bolt IVL System employs a unique laser-based technology, which stands out in terms of precision in energy delivery and treatment effectiveness. This allows Boston Scientific to capture the attention of doctors and patients with the Bolt IVL System when facing competition from Johnson & Johnson, thereby vying for market share.

Abbott's Actions in the IVL Field Should Not Be Overlooked. In March this year, Abbott received FDA Investigational Device Exemption to assess the safety and effectiveness of its coronary IVL technology. This indicates that Abbott is also actively positioning itself in the IVL field, attempting to secure a share in this promising market. With Abbott’s entry, competition in the IVL sector has intensified. Major companies have launched all-around competition in technology research and development, product innovation, and market promotion. This fierce competition will drive companies to increase R&D investment, continuously optimize IVL technologies and products, enhance treatment efficacy and safety, and provide patients with more and better treatment options. Meanwhile, the competition will also promote the refinement and standardization of industry norms, fostering the healthy development of IVL technology.

Impact on the Medical Industry and Patients

(1) Industry Impact

Boston Scientific Acquires Bolt Medical, Injecting a "Strong Stimulant" into the Development of Cardiovascular Medical Technology and Producing Multi - dimensional and Far - reaching Promoting Effects. From the perspective of technological innovation, IVL technology, as an emerging and highly potential treatment method, brings new ideas and approaches to cardiovascular disease treatment with its unique principles and advantages. Through this acquisition, Boston Scientific has obtained Bolt Medical's R&D achievements and technical platform in the IVL technology field, which will encourage it to increase investment in R&D in this area and promote the continuous iteration and upgrading of IVL technology. In the future, IVL technology may make greater breakthroughs in terms of the accuracy of energy transmission, the stability of treatment effects, and the wide applicability to lesion types, providing more efficient and safer solutions for cardiovascular disease treatment.

In terms of market landscape, this acquisition has also triggered a series of chain reactions. After Johnson & Johnson acquired Shockwave Medical, it gained a significant position in the IVL market. The entry of Boston Scientific disrupted the original market balance, intensifying competition in the IVL market. In order to stand out in the competition, companies will continuously optimize their products and services to enhance market competitiveness. This will not only accelerate the promotion and application of IVL technology but may also prompt other medical companies to reassess their positioning in the cardiovascular field. Some companies that were previously on the sidelines in the IVL sector may be stimulated by market competition to increase R&D investment in this area, attempting to gain a share in this promising market. Meanwhile, companies already established in the IVL space will quicken the pace of technological innovation and product development to address the challenges posed by competitors like Boston Scientific and Johnson & Johnson. This competitive dynamic will drive continuous advancement in the field of cardiovascular medical technology, promoting innovation and progress, and providing patients with more and better treatment options.

(II) Patient Benefits

For the vast number of cardiovascular disease patients, the approval of Bolt Medical's IVL system and the completion of Boston Scientific's acquisition are undoubtedly significant positive news. IVL technology offers patients a more effective treatment option. Before the advent of IVL technology, traditional treatments often proved ineffective for patients with severe calcified lesions. Although coronary artery rotational atherectomy can remove calcified plaques, the surgical risks are relatively high and may cause considerable damage to blood vessels. In contrast, IVL technology utilizes unique acoustic pressure waves to effectively break down calcified plaques without injuring the vascular endothelium, creating favorable conditions for subsequent interventional treatments. This provides new hope for patients who were previously unable to undergo traditional treatments due to severe calcified lesions.

Minimally Invasive Treatment: A Significant Advantage of IVL Technology

From clinical cases, many patients have already benefited from IVL technology. One patient with severe coronary artery calcification lesions experienced significant improvement in vascular stenosis and restored normal blood supply to the heart after receiving IVL treatment. Symptoms such as chest pain were also effectively relieved. The patient's quality of life improved significantly, allowing them to resume various daily activities. These successful cases fully demonstrate the effectiveness and safety of IVL technology, giving more patients high hopes for this new treatment method.

Summary and Outlook

Boston Scientific Corporation's Acquisition of Bolt Medical, Inc. Marks a Significant Milestone in the Cardiovascular Healthcare Field

Looking ahead, with the continuous development and improvement of IVL technology, as well as the active participation of more enterprises, the treatment of cardiovascular diseases is expected to usher in more diversified and personalized solutions. We have reason to believe that, under the continuous advancement of medical technology, patients with cardiovascular diseases will receive more efficient and safer treatments, and their quality of life will also see significant improvement.

Focusing on cardiovascular health means focusing on the future of ourselves and our families. Let us jointly look forward to more surprises brought by medical technology innovation in the prevention and treatment of cardiovascular diseases, and hope everyone can pay attention to cardiovascular health and actively prevent the occurrence of cardiovascular diseases.